Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31843
Title: 18F-labeling and initial in vivo evaluation of a Hitomi peptide for imaging tissue transglutaminase 2.
Austin Authors: Ackermann, Uwe ;Jäger, Luise;Rigopoulos, Angela;Burvenich, Ingrid Julienne Georgette;O'Keefe, Graeme Joseph;Scott, Andrew M 
Affiliation: Olivia Newton-John Cancer Research Institute
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Faculty of Medicine, The University of Melbourne, Melbourne, Australia
Molecular Imaging and Therapy
Faculty of Medicine, Eberhard Karls Universität Tübingen, Germany.
Issue Date: 2023
Date: 2022
Publication information: Nuclear Medicine and Biology 2023; 116-117
Abstract: Tissue transglutaminase 2 (TG2) is a calcium-dependent enzyme which cross-links proteins. It is overexpressed in many diseases and plays a key role in tissue remodeling, including cell adhesion and migration. Overexpression of TG2 in breast cancer is a marker for patients at risk of recurrence. Non-invasive imaging of TG2 can therefore play an important role in patient management. TG2 probes labeled with the positron emitters 11C and 18F have thus far not found widespread application due to purity and metabolism issues. Our approach was to radiolabel a TG2 selective, 13-mer amino acid peptide, which was modified with a 5-azidopentanoic acid group at the N-terminus via a copper free click chemistry approach.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31843
DOI: 10.1016/j.nucmedbio.2022.11.002
ORCID: 
Journal: Nuclear Medicine and Biology
Start page: 108308
PubMed URL: 36502585
ISSN: 1872-9614
Type: Journal Article
Subjects: Fluorine-18
Hitomi peptide
PET imaging
Transglutaminase 2
Appears in Collections:Journal articles

Show full item record

Page view(s)

66
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.